A 1-for-20 reverse stock split was implemented on January 26, 2018. Clinical Trials & Near-term Catalysts: The lead drug candidate is M207 for the treatment of migraine. A long-term safety study of M207 is underway. -- The Company …
SmarTrend identified a Downtrend for Acadia Pharmaceu (NASDAQ:ACAD) on February 28th, 2018 at $26.14. In approximately 2 months, Acadia Pharmaceu has returned 38.63% as of today's recent price of $16.04. Acadia …
This has been a bad year for Biogen (NASDAQ:BIIB) so far -- the biotech's stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia …
This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether ACAD’s current trading price of $32.55 reflective of the actual value of the mid-cap?
In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 ... Despite all of this good news, Acadia stock finished the year up only 4%. Acadia CEO Stephen Davis didn't mention the underwhelming performance of the …
especially with off-label usage and label expansion all very big parts of the ACAD stock story going forward. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time …
The biggest risk facing ACAD stock right now is whether it secures a marketing partner. ACAD looks ready to market Nuplazid alone, which will cause pressure on ACAD stock over the next year. Long term, the promise of Nuplazid will …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD announced the …